Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1978 1
1980 2
1981 1
1982 2
1984 2
1985 4
1986 6
1987 7
1988 4
1989 3
1990 2
1991 12
1992 11
1993 14
1994 11
1995 14
1996 9
1997 14
1998 13
1999 27
2000 24
2001 36
2002 43
2003 52
2004 51
2005 67
2006 83
2007 75
2008 66
2009 78
2010 105
2011 117
2012 164
2013 161
2014 176
2015 191
2016 198
2017 252
2018 313
2019 395
2020 464
2021 539
2022 477
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

3,843 results
Results by year
Filters applied: . Clear all
Page 1
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. D'Haens G, et al. Among authors: pang y. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. Lancet. 2022. PMID: 35644154 Clinical Trial.
Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC.
Suthen S, Lim CJ, Nguyen PHD, Dutertre CA, Lai HLH, Wasser M, Chua C, Lim TKH, Leow WQ, Loh TJ, Wan WK, Pang YH, Soon G, Cheow PC, Kam JH, Iyer S, Kow A, Tam WL, Shuen TWH, Toh HC, Dan YY, Bonney GK, Chan CY, Chung A, Goh BKP, Zhai W, Ginhoux F, Chow PKH, Albani S, Chew V. Suthen S, et al. Among authors: pang yh. Hepatology. 2022 Feb 20. doi: 10.1002/hep.32419. Online ahead of print. Hepatology. 2022. PMID: 35184329
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. Ferrante M, et al. Among authors: pang y. Lancet. 2022 May 28;399(10340):2031-2046. doi: 10.1016/S0140-6736(22)00466-4. Lancet. 2022. PMID: 35644155 Clinical Trial.
Engineered Small Extracellular Vesicles as a FGL1/PD-L1 Dual-Targeting Delivery System for Alleviating Immune Rejection.
Tsai HI, Wu Y, Liu X, Xu Z, Liu L, Wang C, Zhang H, Huang Y, Wang L, Zhang W, Su D, Khan FU, Zhu X, Yang R, Pang Y, Eriksson JE, Zhu H, Wang D, Jia B, Cheng F, Chen H. Tsai HI, et al. Among authors: pang y. Adv Sci (Weinh). 2022 Jan;9(3):e2102634. doi: 10.1002/advs.202102634. Epub 2021 Nov 5. Adv Sci (Weinh). 2022. PMID: 34738731 Free PMC article.
Plant-Derived Compounds as Promising Therapeutics for Vitiligo.
Pang Y, Wu S, He Y, Nian Q, Lei J, Yao Y, Guo J, Zeng J. Pang Y, et al. Front Pharmacol. 2021 Nov 11;12:685116. doi: 10.3389/fphar.2021.685116. eCollection 2021. Front Pharmacol. 2021. PMID: 34858164 Free PMC article. Review.
3,843 results